Among active 13F managers last quarter, 4 opened and 30 added, while 27 reduced; the largest holder to move was Price T Rowe Associates Inc (+44%). Over the last 180 days, 6 insiders sold and none bought, a net -$6.2M in open-market trades.
The legs disagree, or only one of them leans.
369 tracked 13F filers disclose a position in ALKS as of the latest SEC 13F filings, a combined $7.9B in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 29.2M | $1.5B | ▲+3.3% Added · +921K sh | Q2 2026 | |
| 2 | Baker Bros. Advisors LP | 10.0M | $524.6M | —Held | Q2 2026 | |
| 3 | Vanguard Portfolio Management LLC | 9.5M | $497.3M | ▼−0.2% Reduced · −20K sh | Q2 2026 | |
| 4 | State Street Corp | 9.2M | $480.0M | ▼−3.2% Reduced · −305K sh | Q2 2026 | |
| 5 | Vanguard Capital Management LLC | 7.5M | $393.7M | ▲+1.2% Added · +88K sh | Q2 2026 | |
| 6 | Price T Rowe Associates Inc | 6.7M | $353.0M | ▲+44% Added · +2.1M sh | Q2 2026 | |
| 7 | Renaissance Technologies LLC | 6.2M | $217.8M | ▼−7.6% Reduced · −508K sh | Q1 2026 | |
| 8 | American Century Companies Inc | 6.1M | $214.7M | ▲+1.9% Added · +115K sh | Q1 2026 | |
| 9 | Dimensional Fund Advisors LP | 4.5M | $159.9M | ▲+2.5% Added · +110K sh | Q1 2026 | |
| 10 | Geode Capital Management, LLC | 4.5M | $234.7M | ▲+7.1% Added · +296K sh | Q2 2026 | |
| 11 | JPMorgan Chase & Co | 4.1M | $123.7M | ▼−21% Reduced · −1.1M sh | Q1 2026 | |
| 12 | Holocene Advisors, LP | 3.6M | $188.7M | ▲+55% Added · +1.3M sh | Q2 2026 | |
| 13 | Deep Track Capital, LP | 3.6M | $127.0M | ▲+80% Added · +1.6M sh | Q1 2026 | |
| 14 | Commodore Capital LP | 3.0M | $157.2M | ▼−29% Reduced · −1.2M sh | Q2 2026 | |
| 15 | First Trust Advisors LP | 3.0M | $105.0M | ▲+104% Added · +1.5M sh | Q1 2026 | |
| 16 | Primecap Management Co | 2.5M | $89.8M | ▼−0.9% Reduced · −24K sh | Q1 2026 | |
| 17 | Nuveen, LLC | 2.5M | $87.0M | ▲+1.4% Added · +34K sh | Q1 2026 | |
| 18 | Charles Schwab Investment Management Inc | 2.2M | $79.1M | ▲+3.9% Added · +84K sh | Q1 2026 | |
| 19 | BVF Inc | 2.2M | $112.9M | ▲+7.7% Added · +155K sh | Q2 2026 | |
| 20 | Norges Bank | 1.9M | $54.4M | ▲+4.4% Added · +82K sh | Q4 2025 | |
| 21 | Bain Capital Life Sciences Investors, LLC | 1.9M | $101.5M | ▲+218% Added · +1.3M sh | Q2 2026 | |
| 22 | Goldman Sachs Group Inc | 1.9M | $66.6M | ▼−17% Reduced · −385K sh | Q1 2026 | |
| 23 | Loomis Sayles & Co L P | 1.8M | $63.1M | ▼−6.2% Reduced · −118K sh | Q1 2026 | |
| 24 | Morgan Stanley | 1.7M | $61.4M | ▼−8.1% Reduced · −152K sh | Q1 2026 | |
| 25 | Northern Trust Corp | 1.7M | $60.0M | ▲+2.6% Added · +44K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership. 1 value row is withheld because the reported units disagree with same-security peers; share counts are unchanged.
Last quarter, 4 funds opened a new position in ALKS and 30 added to an existing one, while 27 reduced. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Eli Lilly & CoLLY | 198 funds | $86.3B |
| Nvidia CorpNVDA | 194 funds | $380.4B |
| Microsoft CorpMSFT | 194 funds | $235.4B |
| Amazon.com IncAMZN | 194 funds | $188.2B |
| Apple IncAAPL | 187 funds | $270.7B |
| Broadcom IncAVGO | 185 funds | $146.4B |
| Alphabet Inc-CL AGOOGL | 184 funds | $177.0B |
| JPMorgan Chase & CoJPM | 184 funds | $60.1B |
| Visa Inc-Class A SharesV | 184 funds | $58.3B |
| Merck & Co. Inc.MRK | 184 funds | $26.2B |
| Meta Platforms Inc-Class AMETA | 183 funds | $105.3B |
| Johnson & JohnsonJNJ | 183 funds | $44.0B |
Ranked by how many of ALKS's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in ALKS.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Sep 3, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell (S) | 2K | $98K |
| Sep 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell (S) | 9K | $423K |
| Aug 17, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | Sell (S) 2 lots, same day | 8K | $373K |
| Aug 3, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell (S) | 9K | $437K |
| Aug 3, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell (S) | 2K | $99K |
| Aug 3, 2026 | snyderman nancy lynn MD | Director | Sell (S) | 44K | $2.2M |
| Jul 6, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell (S) | 2K | $110K |
| Jul 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell (S) 2 lots, same day | 9K | $464K |
| Jun 12, 2026 | Wright Christopher I | Director | Sell (S) | 2K | $90K |
| Jun 4, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell (S) | 2K | $88K |
| Jun 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell (S) | 9K | $375K |
| May 29, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Sell (S) | 16K | $687K |
One row per insider, day and transaction code; shares and value are summed across the lots. Every lot is on the full insider page and in the filing.
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 46 | 43 | – |
Insiders Form 4 open-market | 0 | 6 | -$6.2M |
US House STOCK Act trades | 1 | 0 | +$33K |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for ALKS
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/ALKS/capital-change-brief"
Use Arkolith's capital_change_brief for ALKS. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for ALKS. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.